Verdad Advisers’s Spero Therapeutics SPRO Stock Holding History

Verdad Advisers’s Portfolio SPRO Stock Details SPRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$113K	Buy	51,335 +17,880	+53%	+$46.8K	0.11%	182
2026 Q1	$78.3K	Buy	+33,455	New	+$79.4K	0.09%	163

Other funds holding SPRO

GSK plc London $602M AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Verdad Advisers's SPRO Position: Q2 2026 in Review

Verdad Advisers increased its Spero Therapeutics (SPRO) stake by 53% in Q2 2026, buying an estimated $46.8K and bringing the position to 51,335 shares worth $113K. The position accounts for 0.11% of the portfolio, ranked #182.

Verdad Advisers first reported a position in SPRO in Q1 2026 and has held it in 2 quarters since. 60 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

Verdad Advisers held 51,335 shares of Spero Therapeutics worth $113K as of Q2 2026.
Verdad Advisers bought 17,880 Spero Therapeutics shares in Q2 2026, an estimated $46.8K.
Spero Therapeutics made up 0.11% of Verdad Advisers's portfolio in Q2 2026, its #182 holding.
Verdad Advisers first reported a position in Spero Therapeutics in Q1 2026 and has held it in 2 quarters since.
60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.